Chesley Taft & Associates LLC Buys 14,776 Shares of Johnson & Johnson $JNJ

Chesley Taft & Associates LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 7.5% in the fourth quarter, Holdings Channel reports. The firm owned 212,903 shares of the company’s stock after purchasing an additional 14,776 shares during the quarter. Johnson & Johnson accounts for about 1.7% of Chesley Taft & Associates LLC’s investment portfolio, making the stock its 12th largest position. Chesley Taft & Associates LLC’s holdings in Johnson & Johnson were worth $44,060,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in JNJ. Cypress Wealth Services LLC increased its stake in Johnson & Johnson by 71.2% in the fourth quarter. Cypress Wealth Services LLC now owns 12,272 shares of the company’s stock valued at $2,540,000 after acquiring an additional 5,103 shares during the last quarter. Waldron Private Wealth LLC boosted its holdings in shares of Johnson & Johnson by 0.6% in the 4th quarter. Waldron Private Wealth LLC now owns 25,844 shares of the company’s stock valued at $5,348,000 after purchasing an additional 144 shares in the last quarter. LVW Advisors LLC boosted its holdings in shares of Johnson & Johnson by 1.7% in the 4th quarter. LVW Advisors LLC now owns 24,623 shares of the company’s stock valued at $5,096,000 after purchasing an additional 402 shares in the last quarter. Worth Asset Management LLC increased its stake in shares of Johnson & Johnson by 32.6% in the 4th quarter. Worth Asset Management LLC now owns 3,658 shares of the company’s stock valued at $757,000 after purchasing an additional 899 shares during the last quarter. Finally, Mirador Capital Partners LP raised its holdings in shares of Johnson & Johnson by 13.8% during the 4th quarter. Mirador Capital Partners LP now owns 6,879 shares of the company’s stock worth $1,424,000 after buying an additional 833 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares in the company, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 30,142 shares of company stock valued at $7,360,528. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $242.22 on Tuesday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $583.40 billion, a PE ratio of 21.92, a P/E/G ratio of 2.37 and a beta of 0.34. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $251.71. The stock has a 50-day moving average price of $237.87 and a two-hundred day moving average price of $211.39.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The company had revenue of $24.28 billion for the quarter. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, February 24th. Johnson & Johnson’s payout ratio is presently 47.06%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Bank of America reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, March 2nd. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Thursday, March 5th. TD Cowen lifted their price target on shares of Johnson & Johnson from $222.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Finally, Leerink Partners increased their price objective on shares of Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $236.91.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Royalty Pharma agreed to provide $500 million of R&D co‑funding for JNJ‑4804, a novel co‑antibody targeting IL‑23 and TNF; the deal de‑risks development costs, validates the program and accelerates immunology exposure for J&J. Royalty Pharma and J&J partner to develop autoimmune treatment Johnson & Johnson’s JNJ-4804 Deal Adds Weight To Immunology Story
• Positive Sentiment: J&J presented first randomized Phase 2 data for JNJ‑1900 (NBTXR3) in stage‑3 inoperable lung cancer at a major conference — early positive clinical readouts support the oncology pipeline and partner collaborations. NANOBIOTIX Announces Presentation of First Data
• Positive Sentiment: Johnson & Johnson MedTech shared favorable findings for the Impella CP device in left‑ventricular support at ACC, which may support near‑term MedTech revenue momentum and competitive positioning. Johnson & Johnson MedTech shares findings for Impella CP
• Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” rating and a $255 price target, providing analyst backing that supports upside expectations versus current levels. RBC reaffirmation / Benzinga
• Positive Sentiment: Multiple outlets highlighted J&J as a top dividend/defensive stock and noted an upcoming dividend increase window — this bolsters demand from income and defensive investors given J&J’s low beta and long dividend history. This is Why Johnson & Johnson is a Great Dividend Stock Dividend increases coverage
• Neutral Sentiment: Industry research forecasts growth in the non‑muscle invasive bladder cancer market and lists J&J among leading competitors — a positive long‑term market backdrop but not an immediate catalyst. Non‑Muscle Invasive Bladder Cancer Market report

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.